Reactions 1680, p88 - 2 Dec 2017 Haematological disorders and hair loss: case report An adult woman in her 30’s [exact age at onset not stated] developed grade 4 neutropenia, grade 4 anaemia, grade 3 thrombocytopenia and grade 2 hair loss during treatment with cisplatin and etoposide [dosages, routes, time to reactions onsets and outcomes not stated]. The woman presented with colonic polyposis at the age of 36 and underwent a right hemicolectomy. After the operation, she was given a pathological diagnosis of mixed adenoneuroendocrine carcinoma pT1b N0 M0 stage I. She further developed multiple liver metastases and impaired liver function. She underwent chemotherapy with various drugs but her multiple liver metastases continued to grow larger and she also developed bone, ovary and lymph nodes metastases. Therefore, she was started on third-line chemotherapy with cisplatin plus etoposide. Subsequently, she developed grade 4 neutropenia, grade 4 anaemia, grade 3 thrombocytopenia and grade 2 hair loss. As a result of the ADR’s, she underwent 50% dose reduction of the drugs. The chemotherapy with cisplatin plus etoposide was continued for a further 4 courses but the metastatic lesions developed into progressive disease. As a result, amrubicin monotherapy was administered to the patient as the fourth-line chemotherapy. However, a clinical response was not observed and she died 20 months after the operation due to the metastatic mixed adenoneuroendocrine carcinoma. Author comment: "Therefore, the regimen was changed to cisplatin plus etoposide (EP) as the third-line chemotherapy. In the first course of the chemotherapy, the patient experienced Grade 4 neutropenia, Grade 4 anemia, Grade 3 thrombocytopenia, and Grade 2 hair loss." "[S]ome countries recommend EP regimen for the treatment. . . these regimens have a good response rate, many serious adverse events, particularly hematological toxicity, have been reported." Tagai N, et al. Favorable response of colonic mixed adenoneuroendocrine carcinoma to streptozocin monotherapy. International Cancer Conference Journal 6: 175-179, No. 4, Oct 2017. Available from: URL: http://doi.org/10.1007/ s13691-017-0301-2 - Japan 803285114 0114-9954/17/1680-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved Reactions 2 Dec 2017 No. 1680
Reactions Weekly – Springer Journals
Published: Dec 2, 2017
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera